High-grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used in peritoneal carcinomatosis (PC) management. This modality is criticized for its high morbidity and mortality. We evaluate the morbidity and mortality of patients undergoing this proced...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2020-05, Vol.25 (5), p.984-994
Main Authors: Tan, Joey Wee-Shan, Tan, Grace Hwei Ching, Ng, Wai Yee, Ong, Chin-Ann Johnny, Chia, Claramae Shulyn, Soo, Khee Chee, Teo, Melissa Ching Ching
Format: Article
Language:English
Subjects:
Cancer Research
Chemotherapy
Gastric cancer
Medical prognosis
Medicine
Medicine & Public Health
Morbidity
Mortality
Oncology
Original Article
Peritoneum
Risk factors
Surgery
Surgical Oncology
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used in peritoneal carcinomatosis (PC) management. This modality is criticized for its high morbidity and mortality. We evaluate the morbidity and mortality of patients undergoing this procedure in our institution. Methods A review of our institution’s database was performed. All patients who underwent CRS/HIPEC between July 2011 and March 2018 were divided into three groups: no, low-grade, and high-grade complications. Prognostic factors were determined with Cox regression, while morbidity risk factors were analyzed using multinomial logistic regression. Results 225 consecutive patients underwent CRS/HIPEC. The most common primary cancer types were colorectal (35.1%), appendiceal (25.8%), and ovarian (22.2%). Median age was 55 years old (range 14–77), and patients were typically female (68.0%). 38.7% developed low-grade complications and 14.7% had high-grade complications. No 30-day mortality was observed. Different tumor origins are associated with significant differences in overall survival ( p  
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-019-01609-5